Sponsor Pipeline

Innovent Biologics (Suzhou) Co. Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
27
Active Trials
11
Recruiting
7
Phase 3
8
Disease Areas
9
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT06184568
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and…
Trial completed
2026-06-12 NCT06184568
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and…
date change Completion moved earlier: 2026-06-30 -> 2026-02-09
2026-06-05 NCT07559019
Safety and Preliminary Activity of BI115 in Advanced SCLC
Recruitment opened
2026-06-04 NCT07483554
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
Recruitment opened
2026-06-03 NCT07483567
IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of…
Recruitment opened
2026-05-28 NCT07469800
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Recruitment opened
2026-05-27 NCT07456839
A Mutiple-dose Study of IBI3033 in Healthy Participants
overall status: "Not Yet Recruiting" → "Active Not Recruiting"
2026-05-23 NCT07311226
A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants
overall status: "Not Yet Recruiting" → "Active Not Recruiting"
2026-05-16 NCT07502534
A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in…
overall status: "Not Yet Recruiting" → "Active Not Recruiting"
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-03 NCT07622368 A Study of IBI3031 in Participants With Thyroid Eye Disease Phase 1 Not Yet Recruiting
2026-06-03 NCT07623798 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Phase 3 Not Yet Recruiting
2026-05-28 NCT07612137 Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced… Phase 1/2 Not Yet Recruiting
2026-05-15 NCT07591519 Clinical Trials of IBI3035 in Healthy Subjects Phase 1 Not Yet Recruiting
Active Trials by Phase
Phase 3
7
Phase 2
6
Phase 1/2
2
Phase 1
12
Active Trials — top 25 of 27
NCT IDTitleConditionStatus
Phase 3
NCT07255209 A Study of IBI362 in Chinese Adolescents With Obesity or Overweight Adolescents With Obesity or Overweight With Weight-Related Comorbidities Recruiting
NCT07473960 IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia Recruiting
NCT07469800 Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity Overweight Recruiting
NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With… Overweight Active, Not Recruiting
NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's… Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Active, Not Recruiting
NCT05890742 A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With… MSI-H Active, Not Recruiting
NCT07623798 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Relapsed or Refractory Multiple Myeloma Not Yet Recruiting
Phase 2
NCT07399067 A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis Atopic Dermatitis Recruiting
NCT07330934 A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe… Atopic Dermatitis Recruiting
NCT07483567 IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of… CLDN18.2 Positive Recruiting
NCT07483554 IBI343 in Combination Therapy for Advanced Malignant Solid Tumors CLDN18.2 Positive Recruiting
NCT07352969 A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients Hypertension Not Yet Recruiting
NCT07402070 IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer Resectable Stage II-III Non-small Cell Lung Cancer Not Yet Recruiting
Phase 1/2
NCT06974812 IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors Unresectable Locally Advanced or Metastatic Solid Tumors Recruiting
NCT07612137 Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced… Solid Tumor Not Yet Recruiting
Phase 1
NCT07554222 Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by… Healthy Recruiting
NCT05458219 A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or… Locally Advanced Unresectable or Metastatic Solid Tumors Recruiting
NCT07559019 Safety and Preliminary Activity of BI115 in Advanced SCLC Small Cell Lung Cancer (SCLC) Recruiting
NCT05290597 A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in… Solid Malignancies or Lymphomas Active, Not Recruiting
NCT07549984 A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis Atopic Dermatitis Not Yet Recruiting
NCT07556796 Study of IBI3016 in People With Mild or Moderate Hypertension Patients Hypertension Not Yet Recruiting
NCT07502534 A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in… Healthy Volunteers Active, Not Recruiting
NCT07591519 Clinical Trials of IBI3035 in Healthy Subjects Healthy Person Not Yet Recruiting
NCT07311226 A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants Healthy Participants Active, Not Recruiting
NCT07456839 A Mutiple-dose Study of IBI3033 in Healthy Participants Healthy Participants Active, Not Recruiting
View all 27 active Innovent Biologics (Suzhou) Co. Ltd. trials with filters →
Disease Areas
Get alerts when Innovent Biologics (Suzhou) Co. Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free